We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic Receives FDA Nod for Altaviva Device: Stock to Gain?
Read MoreHide Full Article
Key Takeaways
Medtronic secured FDA approval for its Altaviva implantable tibial neuromodulation device.
MDT's device treats urge urinary incontinence through a minimally invasive ankle implant.
MDT's Altaviva features a 15-year battery life, quick recharging, and MRI compatibility.
Medtronic plc (MDT - Free Report) recently received Food and Drug Administration (“FDA”) approval for the minimally invasive implantable tibial neuromodulation (ITNM) Altaviva device. The therapy is inserted near the ankle and designed to treat urge urinary incontinence. The device represents a transformative milestone, ushering in a new bladder control therapy with advanced features.
The recent development is expected to bolster the company’s Neuromodulation division.
Likely Trend of MDT Stock Following the News
Following the announcement, MDT shares dipped 0.5%, closing at $95.08 on last Friday. On a promising note, over the past 30 years, Medtronic has established itself as the global leader in neuromodulation by consistently pushing the boundaries of innovation.
With the introduction of the Altaviva device, MDT has become the only company with a full portfolio of neuromodulation therapies for these bladder control symptoms. We expect the latest milestone achievements to support the company’s revenue growth and help a rebound in the stock’s performance.
Medtronic has a market capitalization of $121.80 billion. The Zacks Consensus Estimate for fiscal 2026 revenues indicates 6.8% growth over fiscal 2025. MDT beat on earnings in each of the trailing four quarters, the average surprise being 2.20%.
About MDT’s Altaviva device
The device represents a significant advancement for patients with urge urinary incontinence who often weigh the invasiveness of a therapy and the potential side effects when considering treatment options. The device is inserted near the ankle during a minimally invasive procedure that doesn't require sedation or imaging. It then sits slightly below the skin and above the fascia. It sends electrical impulses to the tibial nerve, helping restore communication between the bladder and the brain to regulate bladder control.
The device is designed to have a 15-year battery lifespan under expected therapy settings and delivers therapy automatically, requiring no daily intervention or manual adjustment from the patient. Recharging will take up to 30 minutes when using the default recharging speed, eliminating the need for daily at-home charging equipment. Designed for real-life needs, the Altaviva device is MRI-compatible, providing patients with peace of mind for planned or unexpected medical imaging.
Image Source: Zacks Investment Research
Industry Prospects Favor MDT
Per Medtronic’s management, bladder control problems affect an estimated 43 million, or one in six, U.S. adults. Of those, nearly 16 million people have urge urinary incontinence, a common symptom of overactive bladder (OAB) characterized by a sudden, intense urge to urinate, often followed by involuntary leaks before reaching the bathroom. In addition, per a report by the Grand View Research, the global urinary incontinence therapeutics market size is projected to witness a CAGR of 4.0% from 2024 to 2030, driven by a growing aging population and rising awareness.
Another Update by MDT
Earlier this month, Medtronic announced two regulatory milestones for its MiniMed 780G system portfolio. The FDA has cleared the company’s SmartGuard algorithm as an interoperable automated glycemic controller, enabling integration with Abbott’s (ABT) Instinct sensor for type 1 diabetes. In addition, the MiniMed 780G system secured approval for use in adults aged 18 and above, with insulin-requiring type 2 diabetes.
MDT Stock Price Performance
In the past year, Medtronic shares have risen 5.8% compared with the industry’s 0.3% growth.
MDT’s Zacks Rank and Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold).
Masimo’s shares have jumped 18.9% in the past year. Estimates for the company’s 2025 earnings per share have increased 5.2% to $5.24 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%.
Estimates for Phibro Animal Health’s fiscal 2026 earnings per share have climbed 5 cents to $2.35 in the past 30 days. Shares of the company have surged 76.5% in the past year compared with the industry’s 3.4% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%.
Estimates for Envista’s 2025 earnings per share have increased 7.6% in the past 30 days. Shares of the company have rallied 16.7% in the past year compared with the industry’s 5.2% growth. Its earnings yield of 5.4% has also outpaced the industry’s -0.9%. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medtronic Receives FDA Nod for Altaviva Device: Stock to Gain?
Key Takeaways
Medtronic plc (MDT - Free Report) recently received Food and Drug Administration (“FDA”) approval for the minimally invasive implantable tibial neuromodulation (ITNM) Altaviva device. The therapy is inserted near the ankle and designed to treat urge urinary incontinence. The device represents a transformative milestone, ushering in a new bladder control therapy with advanced features.
The recent development is expected to bolster the company’s Neuromodulation division.
Likely Trend of MDT Stock Following the News
Following the announcement, MDT shares dipped 0.5%, closing at $95.08 on last Friday. On a promising note, over the past 30 years, Medtronic has established itself as the global leader in neuromodulation by consistently pushing the boundaries of innovation.
With the introduction of the Altaviva device, MDT has become the only company with a full portfolio of neuromodulation therapies for these bladder control symptoms. We expect the latest milestone achievements to support the company’s revenue growth and help a rebound in the stock’s performance.
Medtronic has a market capitalization of $121.80 billion. The Zacks Consensus Estimate for fiscal 2026 revenues indicates 6.8% growth over fiscal 2025. MDT beat on earnings in each of the trailing four quarters, the average surprise being 2.20%.
About MDT’s Altaviva device
The device represents a significant advancement for patients with urge urinary incontinence who often weigh the invasiveness of a therapy and the potential side effects when considering treatment options. The device is inserted near the ankle during a minimally invasive procedure that doesn't require sedation or imaging. It then sits slightly below the skin and above the fascia. It sends electrical impulses to the tibial nerve, helping restore communication between the bladder and the brain to regulate bladder control.
The device is designed to have a 15-year battery lifespan under expected therapy settings and delivers therapy automatically, requiring no daily intervention or manual adjustment from the patient. Recharging will take up to 30 minutes when using the default recharging speed, eliminating the need for daily at-home charging equipment. Designed for real-life needs, the Altaviva device is MRI-compatible, providing patients with peace of mind for planned or unexpected medical imaging.
Image Source: Zacks Investment Research
Industry Prospects Favor MDT
Per Medtronic’s management, bladder control problems affect an estimated 43 million, or one in six, U.S. adults. Of those, nearly 16 million people have urge urinary incontinence, a common symptom of overactive bladder (OAB) characterized by a sudden, intense urge to urinate, often followed by involuntary leaks before reaching the bathroom. In addition, per a report by the Grand View Research, the global urinary incontinence therapeutics market size is projected to witness a CAGR of 4.0% from 2024 to 2030, driven by a growing aging population and rising awareness.
Another Update by MDT
Earlier this month, Medtronic announced two regulatory milestones for its MiniMed 780G system portfolio. The FDA has cleared the company’s SmartGuard algorithm as an interoperable automated glycemic controller, enabling integration with Abbott’s (ABT) Instinct sensor for type 1 diabetes. In addition, the MiniMed 780G system secured approval for use in adults aged 18 and above, with insulin-requiring type 2 diabetes.
MDT Stock Price Performance
In the past year, Medtronic shares have risen 5.8% compared with the industry’s 0.3% growth.
MDT’s Zacks Rank and Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Phibro Animal Health (PAHC - Free Report) and Envista (NVST - Free Report) . Masimo, Phibro and Envista carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Masimo’s shares have jumped 18.9% in the past year. Estimates for the company’s 2025 earnings per share have increased 5.2% to $5.24 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%.
Estimates for Phibro Animal Health’s fiscal 2026 earnings per share have climbed 5 cents to $2.35 in the past 30 days. Shares of the company have surged 76.5% in the past year compared with the industry’s 3.4% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%.
Estimates for Envista’s 2025 earnings per share have increased 7.6% in the past 30 days. Shares of the company have rallied 16.7% in the past year compared with the industry’s 5.2% growth. Its earnings yield of 5.4% has also outpaced the industry’s -0.9%. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.